Johnson & Johnson (NYSE:JNJ) on Tuesday reported a first-quarter 2025 adjusted earnings of $2.70 per share, down 2.5% year over year, beating the consensus of $2.67.
The U.S. healthcare giant reported sales of $24.06 billion, up 9.9% year over year and beating the consensus of $23.63 billion.
Operational growth was 6.4%, and adjusted operational growth was 5.3%.
Innovative Medicine Growth Driven By Oncology And Neuroscience
Innovative Medicine sales increased 11.2% or 7.4% operationally to $15.43 billion.
Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze in oncology, Tremfya (guselkumab), and Spravato (esketamine) in neuroscience primarily drove growth.
However, Stelara in Immunology and Imbruvica in Oncology partially offset growth, with Stelara contributing an approximate 920-basis-point impact.
Cancer drug sales increased …